Allurion Technologies (NYSE:ALUR – Get Free Report) and InMode (NASDAQ:INMD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Insider & Institutional Ownership
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Allurion Technologies and InMode’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allurion Technologies | -199.96% | N/A | -77.13% |
| InMode | 25.33% | 14.52% | 12.88% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allurion Technologies | 1 | 2 | 1 | 0 | 2.00 |
| InMode | 1 | 7 | 1 | 0 | 2.00 |
Allurion Technologies currently has a consensus target price of $9.25, suggesting a potential upside of 714.98%. InMode has a consensus target price of $16.80, suggesting a potential upside of 17.48%. Given Allurion Technologies’ higher possible upside, research analysts clearly believe Allurion Technologies is more favorable than InMode.
Risk & Volatility
Allurion Technologies has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.
Valuation & Earnings
This table compares Allurion Technologies and InMode”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allurion Technologies | $32.11 million | 0.43 | -$7.20 million | ($10.56) | -0.11 |
| InMode | $370.49 million | 2.45 | $93.83 million | $1.44 | 9.93 |
InMode has higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats Allurion Technologies on 10 of the 12 factors compared between the two stocks.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
